thyroid cancer
Conditions
Interventions
Conventional open surgery + tracer group :Mitoxantrone Hydrochloride Injection for Tracing was used
TOETVA + tracer group:Mitoxantrone Hydrochloride Injection for Tracing was used
Conventional open surgery + tracer group :NONE
TOETVA + no tracer group:NONE
Sponsors
Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age of 18-70 years old (including 18 and 70 years old), male and female 2. Preoperative clinical diagnosis of thyroid cancer, planned to undergo radical resection of thyroid cancer 3. According to preoperative evaluation, thyroid lobe/total resection + cervical lymph node dissection was planned 4. No obvious surgical contraindications were found in routine preoperative examination 5. Able to communicate well with researchers and complete research according to research regulations 6. Patients voluntarily participated in this study and signed informed consent. Note: The standard of "lobectomy/total thyroidectomy + neck lymph node dissection" referred to the 2015 American Thyroid Association Management Guidelines for Adult Patientswith Thyroid Nodules and Differentiated Thyroid Cancer
Exclusion criteria
Exclusion criteria: 1. Hypersensitive constitution, or a history of severe drug allergy, or allergic to anthraquinones 2. A history of drug abuse in the past 1 year 3. Patients with a history of thyroid surgery, thyroid isotope therapy or neck radiotherapy 4. Hemoglobin (HB) 3 times the upper limit of normal (ALT and AST in patients with liver metastases > 5 times the upper limit of normal) 6. Serum creatinine (Cr) > 1.5 times upper limit of normal (ULN) 7. Participants who participated in other clinical trials within 3 months before the trial 8. Patients with neurological disease, mental illness or intellectual disability who cannot correctly describe their feelings 9. Pregnant and lactating women 10. The subjects and their spouses plan to conceive during the trial and within 6 months after the trial 11. The research personnel of the trial are not allowed to participate in the study as subjects. 12. In addition to the above, subjects judged by the investigator to be unfit to participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lymph tracing rate;The rate of improper parathyroidectomy;Lymphatic staining rate;The rate of parathyroid misstaining; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total number of lymph nodes removed;The total number of metastatic lymph nodes removed;The removed lymph nodes were graded and counted; | — |
Countries
China
Contacts
Public Contactxiaowei peng
Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University.
Outcome results
None listed